For Release to the Market

Neuren Pharmaceuticals Limited
Share Purchase Plan

On 10 July 2009, and as modified on 15 July 2009, Neuren Pharmaceuticals Limited (Neuren or the Company) announced that it would extend its Share Purchase Plan (Plan), offering each shareholder with a registered address in Australia or New Zealand between A$900 and A$15,000 worth of new fully paid ordinary shares in the capital of the Company.

In compliance with the New Zealand Securities Act (Neuren Pharmaceuticals Limited) Exemption Notice 2006 as amended by the New Zealand Securities Act (Neuren Pharmaceuticals Limited) Exemption Amendment Notice 2009, Neuren provides the following information:

1. The subscription price under the Plan has been set at A$0.03 per share. Documentation in relation to the Plan was sent to eligible shareholders on 20 July 2009 and the offer opens on 23 July 2009; and

2. The Board of Directors of Neuren Pharmaceuticals Limited hereby certifies that, at the time when the subscription price was fixed, Neuren Pharmaceuticals Limited had no information not publicly available that would, or would be likely to, have a material effect on the market price of the Company’s shares if the information were publicly available.

Signed by each of the directors of Neuren Pharmaceuticals Limited, or by his agent:

Dr Robin Congreve  
Chairman

Mr Trevor Scott  
Director

Dr Doug Wilson  
Director

Dr Graeme Howie  
Director